SEC Form 4 · accession 0001179110-18-006037
AMAG PHARMACEUTICALS INC. · AMAG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Alan Butcher
Officer — EVP, Chief Business Officer
Period of report
Apr 30, 2018
Accepted (ET)
May 2, 2018 · 8:31 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000792977
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Apr 30, 2018 | A | 28,418 | — | A | 28,418 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3,F4 | $20.55 | Apr 30, 2018 | A | 62,393 | A | — | Apr 30, 2028 | Common Stock | 62,393 | 62,393 | D |
Explanation of responses
- F1Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of AMAG Pharmaceuticals, Inc.
- F2These shares of common stock are issuable pursuant to a grant of RSUs that will vest in three equal annual installments with the first installment vesting on April 30, 2019.
- F3Not applicable.
- F4Grant of stock options that will vest and become exercisable in four equal annual installments commencing on April 30, 2019.